MX9603490A - Adenovirus recombinantes que codifican para el factor neurotrofico derivado del cerebro (bdnf). - Google Patents

Adenovirus recombinantes que codifican para el factor neurotrofico derivado del cerebro (bdnf).

Info

Publication number
MX9603490A
MX9603490A MX9603490A MX9603490A MX9603490A MX 9603490 A MX9603490 A MX 9603490A MX 9603490 A MX9603490 A MX 9603490A MX 9603490 A MX9603490 A MX 9603490A MX 9603490 A MX9603490 A MX 9603490A
Authority
MX
Mexico
Prior art keywords
bdnf
brain
neurotrophic factor
derived neurotrophic
recombinant adenoviruses
Prior art date
Application number
MX9603490A
Other languages
English (en)
Inventor
Laurent Pradier
Pascal Barneoud
Pia Delaere
Michel Perricaudet
Emmanuele Vigne
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of MX9603490A publication Critical patent/MX9603490A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a los adenovirus recombinantes que poseen una secuencia de ADN heterologo, que codifica para el factor neurotrofico derivado de cerebro (BNDF), a su preparacion, y a su utilizacion para el tratamiento y/o la prevencion de enfermedades neurodegenerativas.
MX9603490A 1994-03-18 1995-03-02 Adenovirus recombinantes que codifican para el factor neurotrofico derivado del cerebro (bdnf). MX9603490A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9403191A FR2717496B1 (fr) 1994-03-18 1994-03-18 Virus recombinants, préparation et utilisation en thérapie génique.
PCT/FR1995/000250 WO1995025804A1 (fr) 1994-03-18 1995-03-02 Adenovirus recombinants codant pour le facteur neurotrophique derive du cerveau (bdnf)

Publications (1)

Publication Number Publication Date
MX9603490A true MX9603490A (es) 1997-03-29

Family

ID=9461190

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603490A MX9603490A (es) 1994-03-18 1995-03-02 Adenovirus recombinantes que codifican para el factor neurotrofico derivado del cerebro (bdnf).

Country Status (12)

Country Link
EP (1) EP0750676A1 (es)
JP (1) JPH09510358A (es)
KR (1) KR970701784A (es)
AU (1) AU703793B2 (es)
CA (1) CA2184200A1 (es)
FI (1) FI963674A0 (es)
FR (1) FR2717496B1 (es)
IL (1) IL112992A0 (es)
MX (1) MX9603490A (es)
NO (1) NO963559L (es)
WO (1) WO1995025804A1 (es)
ZA (1) ZA952244B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
FR2753379B1 (fr) * 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
AU5945301A (en) * 2000-05-05 2001-11-20 Res Foundation Of City Univers Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
US20210079050A1 (en) * 2018-02-20 2021-03-18 Carmel Haifa University Economic Corporation Ltd. Compositions and methods for delivery and expression of small inhibitory peptides and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675409B2 (en) * 1991-07-10 1997-02-06 Regeneron Pharmaceuticals, Inc. Methods of treatment of motor neuron diseases using members of the BDNF/NT-3/NGF family of molecules
AU3129793A (en) * 1991-11-08 1993-06-07 General Hospital Corporation, The Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
NZ256018A (en) * 1992-09-25 1997-07-27 Rhone Poulenc Rorer Sa Recombinant adenoviral vectors and their use in directing expression and transcription of selected nucleotide sequences in cells of the central nervous system
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.

Also Published As

Publication number Publication date
KR970701784A (ko) 1997-04-12
WO1995025804A1 (fr) 1995-09-28
FI963674A (fi) 1996-09-17
FR2717496A1 (fr) 1995-09-22
FI963674A0 (fi) 1996-09-17
FR2717496B1 (fr) 1996-04-12
AU1896295A (en) 1995-10-09
EP0750676A1 (fr) 1997-01-02
JPH09510358A (ja) 1997-10-21
CA2184200A1 (fr) 1995-09-28
NO963559L (no) 1996-08-26
IL112992A0 (en) 1995-06-29
ZA952244B (en) 1996-01-16
AU703793B2 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
MX9604024A (es) Virus recombinante, preparacion y utilizacion en terapia genica.
HK1022480A1 (en) Porcine factor viii and hybrids thereof
AU8147294A (en) Recombinant viruses coding for thymidine kinase in gene therapy
AU1235392A (en) Cytokine-induced protein, tsg-14, dna coding therefor and uses thereof
AU2319497A (en) Helper-free, totally defective adenovirus for gene therapy
GR3032628T3 (en) NEW GROWTH/DIFFERENTIATION FACTOR OF THE TGF--g(b) FAMILY
HU9500732D0 (en) Defective adenovirus vectors and use thereof in gene therapy
AU3907889A (en) Dna sequences encoding polypeptides having beta-1, 3-glucanase activity
AU3274995A (en) Fibrin-binding peptides, dna coding therefor and uses thereof
AU2142595A (en) Recombinant adenoviruses coding for basic fibroblast growth factors (bfgf)
MX9705937A (es) Procedimiento de preparacion de genoma de adenovirus recombinantes.
DE69637856D1 (en) Interleukin-19.
WO1994005791A3 (en) Dorsal tissue affecting factor and compositions
ZA979573B (en) (Alpha-aminophosphino) peptide derivatives, process for their preparation and their therapeutic applications.
EP0669396A4 (en) Novel polypeptides and DNA coding for them.
MX9603490A (es) Adenovirus recombinantes que codifican para el factor neurotrofico derivado del cerebro (bdnf).
AU3733497A (en) Recombinant sef14 fimbrial protein from salmonella
EP0606008A3 (en) Gene coding for hyperthermostable beta-galactosidase.
AU6292694A (en) Novel polypeptide, dna coding for said polypeptide, recombinant vector containing said dna, recombinant virus prepared using said vector, and use thereof
HUT64369A (en) Collagen binding protein and method for producing it
AU2820992A (en) Polypeptide, dna fragment encoding the same, drug composition containing the same and process for producing the same
GB9421093D0 (en) Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof
AU1896195A (en) Recombinant adenoviruses coding for acidic fibroblast growth factor (afgf)
ZA966489B (en) New protein human MP52 Arg.
AU7002594A (en) Dna coding for the human thyrotropin-releasing hormone receptor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal